These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35457733)

  • 21. Cost Effectiveness Analysis Using Disability-Adjusted Life Years for Cataract Surgery.
    Rochmah TN; Wulandari A; Dahlui M; Ernawaty ; Wulandari RD
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32824872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.
    Obeng-Kusi M; Habila MA; Roe DJ; Erstad B; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):1-13. PubMed ID: 34866541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring the Benefits of Healthcare: DALYs and QALYs - Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions.
    Augustovski F; Colantonio LD; Galante J; Bardach A; Caporale JE; Zárate V; Chuang LH; Pichon-Riviere A; Kind P
    Int J Health Policy Manag; 2018 Feb; 7(2):120-136. PubMed ID: 29524936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic Burden and Disability-Adjusted Life Years (DALYs) of Attention Deficit/Hyperactivity Disorder.
    Hong M; Park B; Lee SM; Bahn GH; Kim MJ; Park S; Oh IH; Park H
    J Atten Disord; 2020 Apr; 24(6):823-829. PubMed ID: 31364445
    [No Abstract]   [Full Text] [Related]  

  • 25. Haemophilia A: health and economic burden of a rare disease in Portugal.
    Café A; Carvalho M; Crato M; Faria M; Kjollerstrom P; Oliveira C; Pinto PR; Salvado R; Dos Santos AA; Silva C
    Orphanet J Rare Dis; 2019 Sep; 14(1):211. PubMed ID: 31484564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost and disease burden of dengue in Cambodia.
    Beauté J; Vong S
    BMC Public Health; 2010 Aug; 10():521. PubMed ID: 20807395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.
    Zhao FL; Xie F; Hu H; Li SC
    Pharmacoeconomics; 2013 Jun; 31(6):501-8. PubMed ID: 23620212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orthopaedic trauma care in Haiti: a cost-effectiveness analysis of an innovative surgical residency program.
    Carlson LC; Slobogean GP; Pollak AN
    Value Health; 2012; 15(6):887-93. PubMed ID: 22999139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [DALYs for breast cancer in China, 2000-2050: trend analysis and prediction based on GBD 2019].
    Yan XX; Li YJ; Cao MD; Wang H; Liu CC; Wang X; Ran JC; Liang L; Lei L; Peng J; Shi JF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Dec; 42(12):2156-2163. PubMed ID: 34954980
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluating Health Expenditure Trends and Disease Burden in India: A Cost per DALY Approach.
    Bagepally BS; Kumar S S; Sasidharan A
    Clinicoecon Outcomes Res; 2024; 16():187-196. PubMed ID: 38560409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review.
    Ozawa S; Mirelman A; Stack ML; Walker DG; Levine OS
    Vaccine; 2012 Dec; 31(1):96-108. PubMed ID: 23142307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review.
    Oostvogels AJ; De Wit GA; Jahn B; Cassini A; Colzani E; De Waure C; Kretzschmar ME; Siebert U; Mühlberger N; Mangen MJ
    Epidemiol Infect; 2015 Jul; 143(9):1791-802. PubMed ID: 25499823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
    Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
    Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019.
    Safiri S; Kolahi AA; Naghavi M;
    BMJ Glob Health; 2021 Nov; 6(11):. PubMed ID: 34844997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation on the indirect economic burden of stroke using combination of disability-adjusted life years and human capital method].
    Long Y; Liu XD; Duan LP; Lu J; Yan YP; Zhang L; Hu JX; Huang JY; Xu DZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Jul; 28(7):708-11. PubMed ID: 18069566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in disease burden in Poland between 1990-2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017.
    Gańczak M; Miazgowski T; Kożybska M; Kotwas A; Korzeń M; Rudnicki B; Nogal T; Andrei CL; Ausloos M; Banach M; Brazinova A; Constantin MM; Dubljanin E; Herteliu C; Hostiuc M; Hostiuc S; Jakovljevic M; Jozwiak JJ; Kissimova-Skarbek K; Król ZJ; Mestrovic T; Miazgowski B; Milevska Kostova N; Naghavi M; Negoi I; Negoi RI; Pana A; Rubino S; Sekerija M; Sierpinski R; Szponar L; Topor-Madry R; Vujcic IS; Widecka J; Widecka K; Wojtyniak B; Zadnik V; Kopec JA
    PLoS One; 2020; 15(3):e0226766. PubMed ID: 32119685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.
    Murray CJ; Lopez AD
    Lancet; 1997 May; 349(9063):1436-42. PubMed ID: 9164317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost Effectiveness of Implementing Integrated Management of Neonatal and Childhood Illnesses Program in District Faridabad, India.
    Prinja S; Bahuguna P; Mohan P; Mazumder S; Taneja S; Bhandari N; van den Hombergh H; Kumar R
    PLoS One; 2016; 11(1):e0145043. PubMed ID: 26727369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.